Uncategorized

Glutathione is one of the most extensively studied molecules in redox biology — a naturally occurring tripeptide that every human cell manufactures and relies on to manage oxidative stress. Its biological ubiquity has also made it one of the most commercially exploited compounds in the wellness industry, marketed in oral supplements, topical creams, and —

“GLOW” is a combination research product — a single vial containing three separately studied peptides, rather than one compound in its own right. This guide is written for laboratory researchers and institutional buyers evaluating the GLOW blend for legitimate in vitro, ex vivo, or animal research, and it is structured differently from a single-compound guide

DSIP — short for Delta Sleep-Inducing Peptide — is one of the older entries in the peptide research literature, and one whose name may be doing more persuasive work than its evidence base. It was isolated from rabbit cerebral blood in the 1970s in experiments tied to slow-wave (“delta”) sleep, and the name has followed

CJC-1295 is one of the more frequently searched names in the growth-hormone-releasing-hormone (GHRH) analog research space, and one of the more confusingly marketed. The name is used, often inconsistently across vendor websites, to describe two distinct research peptides: CJC-1295 without DAC (more precisely called Modified GRF 1-29, or Mod GRF 1-29) and CJC-1295 with DAC

Cerebrolysin is one of the more unusual entries in the neuroscience research literature, and it is important to say so plainly before anything else: it is not a single, defined peptide. Compounds like BPC-157 or Semax are individual amino acid sequences with one molecular formula and one CAS number. Cerebrolysin is a complex mixture —

Cartalax is a short synthetic peptide belonging to the same “peptide bioregulator” research family as Epitalon, developed out of the St. Petersburg (Khavinson-affiliated) tradition of short-chain regulatory peptide research. It is marketed in the research-chemical trade as a “cartilage bioregulator,” but readers should understand upfront that the published, indexed research base tied specifically to this

AOD9604 is a synthetic fragment of human growth hormone that has circulated in laboratory research for over two decades, most often in the context of lipolysis (fat-metabolism) and adipocyte biology studies. It is sold for research use only (RUO), is not approved by the FDA for any human use, and is not intended for human

AHK-Cu is a copper-binding tripeptide that has drawn interest in dermatological and hair-follicle research as a laboratory tool for studying copper signaling in skin and scalp tissue. It is frequently discussed alongside its better-known relative, GHK-Cu, but the two are chemically distinct molecules with separate (and unequal) research records. The evidence base for AHK-Cu specifically

5-Amino-1MQ is a small-molecule research compound studied for its ability to inhibit an enzyme called nicotinamide N-methyltransferase (NNMT). It has drawn interest in laboratory settings because NNMT activity intersects with adipocyte (fat cell) metabolism, cellular NAD+ availability, and skeletal muscle stem cell function — three areas of active basic-science research. The evidence base for 5-Amino-1MQ

GHK-Cu, also known as copper tripeptide-1 or the copper complex of glycyl-L-histidyl-L-lysine, is one of the more extensively studied naturally occurring peptides in the biomedical literature. It has attracted sustained research interest because it is not a synthetic novelty invented in a lab — it is a small copper-binding tripeptide that human plasma already contains,